Today's Analyst Stock Ratings | Upgrades, Downgrades

							Get Alert
Sep 3, 2026	CMECME Group	$275.29	6.07%	Bill KatzTD Cowen 68%	292 292	Previous Buy Current Buy	Get Alert
Aug 19, 2026	CMECME Group	$275.29	-1.92%	Brian BedellDeutsche Bank 73%	270 286	Previous Buy Current Hold	Get Alert
Jul 23, 2026	CMECME Group	$275.29	-9.19%	Kenneth WorthingtonJP Morgan 54%	249 250	Previous Underweight Current Underweight	Get Alert
Jul 23, 2026	CMECME Group	$275.29	-16.45%	Craig SiegenthalerB of A Securities 72%	226 230	Previous Underperform Current Underperform	Get Alert
Jul 23, 2026	CMECME Group	$275.29	19.87%	Michael CyprysMorgan Stanley 67%	324 330	Previous Overweight Current Overweight	Get Alert
Jul 15, 2026	CMECME Group	$275.29	7.16%	Patrick MoleyPiper Sandler 81%	295 329	Previous Overweight Current Overweight	Get Alert
Jul 10, 2026	CMECME Group	$275.29	17.7%	Michael CyprysMorgan Stanley 67%	324 353	Previous Overweight Current Overweight	Get Alert
Jul 9, 2026	CMECME Group	$275.29	-1.92%	Benjamin BudishBarclays 74%	270 316	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 8, 2026	CMECME Group	$275.29	-1.92%	Bill KatzTD Cowen 68%	270 273	Previous Buy Current Buy	Get Alert
Jul 6, 2026	CMECME Group	$275.29	-5.55%	Alex KrammUBS 70%	260 310	Previous Neutral Current Neutral	Get Alert
Jul 2, 2026	CMECME Group	$275.29	16.24%	Patrick O'ShaughnessyRaymond James 73%	320 320	Previous Outperform Current Outperform	Get Alert
Jun 22, 2026	CMECME Group	$275.29	-0.83%	Bill KatzTD Cowen 68%	273 323	Previous Buy Current Buy	Get Alert
Jun 18, 2026	CMECME Group	$275.29	10.79%	Chris AllenKeefe, Bruyette & Woods 72%	305 305	Previous Market Perform Current Outperform	Get Alert
Jun 11, 2026	CMECME Group	$275.29	17.33%	Simon ClinchRothschild & Co 59%	316 323	Previous Neutral Current Buy	Get Alert
Jun 5, 2026	CMECME Group	$275.29	—	Hans EngelErste Group 63%	—	Previous Buy Current Hold	Get Alert
Apr 23, 2026	CMECME Group	$275.29	17.33%	Bill KatzTD Cowen 68%	323 340	Previous Buy Current Buy	Get Alert
Apr 23, 2026	CMECME Group	$275.29	28.23%	Michael CyprysMorgan Stanley 67%	353 362	Previous Overweight Current Overweight	Get Alert
Apr 23, 2026	CMECME Group	$275.29	14.79%	Benjamin BudishBarclays 74%	316 343	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 15, 2026	CMECME Group	$275.29	19.51%	Patrick MoleyPiper Sandler 81%	313 329	Previous Overweight Current Overweight	Get Alert
Apr 13, 2026	CMECME Group	$275.29	24.6%	Benjamin BudishBarclays 74%	343 344	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 10, 2026	CMECME Group	$275.29	31.5%	Michael CyprysMorgan Stanley 67%	340 362	Previous Overweight Current Overweight	Get Alert
Apr 9, 2026	CMECME Group	$275.29	23.51%	Bill KatzTD Cowen 68%	328 340	Previous Buy Current Buy	Get Alert
Apr 8, 2026	CMECME Group	$275.29	24.96%	Benjamin BudishBarclays 74%	312 344	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 8, 2026	CMECME Group	$275.29	10.79%	Chris AllenKeefe, Bruyette & Woods 72%	305	Previous Market Perform Current Market Perform	Get Alert
Mar 4, 2026	CMECME Group	$275.29	—	Stephen BiggarArgus Research 75%	—	Previous Buy Current Hold	Get Alert
Feb 6, 2026	CMECME Group	$275.29	12.61%	Alex KrammUBS 70%	280 310	Previous Neutral Current Neutral	Get Alert
Feb 5, 2026	CMECME Group	$275.29	-3.37%	Kenneth WorthingtonJP Morgan 54%	262 266	Previous Underweight Current Underweight	Get Alert
Feb 5, 2026	CMECME Group	$275.29	19.15%	Bill KatzTD Cowen 68%	305 328	Previous Buy Current Buy	Get Alert
Feb 5, 2026	CMECME Group	$275.29	13.34%	Benjamin BudishBarclays 74%	304 312	Previous Equal-Weight Current Equal-Weight	Get Alert
Feb 5, 2026	CMECME Group	$275.29	9.7%	Ashish SabadraRBC Capital 73%	295 302	Previous Sector Perform Current Sector Perform	Get Alert
Feb 5, 2026	CMECME Group	$275.29	23.51%	Michael CyprysMorgan Stanley 67%	319 340	Previous Overweight Current Overweight	Get Alert
Jan 15, 2026	CMECME Group	$275.29	15.88%	Michael CyprysMorgan Stanley 67%	319 320	Previous Overweight Current Overweight	Get Alert
Jan 14, 2026	CMECME Group	$275.29	10.79%	Bill KatzTD Cowen 68%	290 305	Previous Hold Current Buy	Get Alert
Dec 22, 2025	CMECME Group	$275.29	16.24%	Michael CyprysMorgan Stanley 67%	314 320	Previous Overweight Current Overweight	Get Alert
Dec 12, 2025	CMECME Group	$275.29	10.43%	Benjamin BudishBarclays 74%	280 304	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 13, 2025	CMECME Group	$275.29	13.7%	Patrick MoleyPiper Sandler 81%	296 313	Previous Overweight Current Overweight	Get Alert
Oct 23, 2025	CMECME Group	$275.29	14.06%	Michael CyprysMorgan Stanley 67%	312 314	Previous Overweight Current Overweight	Get Alert
Oct 23, 2025	CMECME Group	$275.29	1.71%	Alex KrammUBS 70%	280 285	Previous Neutral Current Neutral	Get Alert
Oct 23, 2025	CMECME Group	$275.29	8.98%	Brian BedellDeutsche Bank 73%	266 300	Previous Hold Current Buy	Get Alert
Oct 13, 2025	CMECME Group	$275.29	11.52%	Patrick O'ShaughnessyRaymond James 73%	307 309	Previous Outperform Current Outperform	Get Alert
Oct 8, 2025	CMECME Group	$275.29	1.71%	Benjamin BudishBarclays 74%	280 298	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 1, 2025	CMECME Group	$275.29	13.34%	Michael CyprysMorgan Stanley 67%	303 312	Previous Overweight Current Overweight	Get Alert
Sep 25, 2025	CMECME Group	$275.29	-8.46%	Kenneth WorthingtonJP Morgan 54%	246 252	Previous Underweight Current Underweight	Get Alert
Sep 25, 2025	CMECME Group	$275.29	8.98%	Christopher AllenCitigroup 67%	275 300	Previous Neutral Current Buy	Get Alert
Sep 8, 2025	CMECME Group	$275.29	3.53%	Alex KrammUBS 70%	285 305	Previous Neutral Current Neutral	Get Alert
Jul 24, 2025	CMECME Group	$275.29	10.79%	Alex KrammUBS 70%	305 305	Previous Buy Current Neutral	Get Alert
Jul 24, 2025	CMECME Group	$275.29	10.07%	Owen LauOppenheimer 64%	300 303	Previous Outperform Current Outperform	Get Alert
Jul 24, 2025	CMECME Group	$275.29	8.25%	Benjamin BudishBarclays 74%	298 299	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 15, 2025	CMECME Group	$275.29	7.52%	Patrick MoleyPiper Sandler 81%	283 296	Previous Overweight Current Overweight	Get Alert
Jul 10, 2025	CMECME Group	$275.29	8.61%	Benjamin BudishBarclays 74%	283 299	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 3, 2025	CMECME Group	$275.29	-0.1%	Christopher AllenCitigroup 67%	265 275	Previous Neutral Current Neutral	Get Alert
Jun 4, 2025	CMECME Group	$275.29	8.98%	Owen LauOppenheimer 64%	282 300	Previous Outperform Current Outperform	Get Alert
Apr 25, 2025	CMECME Group	$275.29	10.79%	Alex KrammUBS 70%	290 305	Previous Buy Current Buy	Get Alert
Apr 24, 2025	CMECME Group	$275.29	10.43%	Michael CyprysMorgan Stanley 67%	301 304	Previous Overweight Current Overweight	Get Alert
Apr 24, 2025	CMECME Group	$275.29	2.44%	Owen LauOppenheimer 64%	279 282	Previous Outperform Current Outperform	Get Alert
Apr 24, 2025	CMECME Group	$275.29	-0.83%	Kyle VoigtKeefe, Bruyette & Woods 61%	265 273	Previous Market Perform Current Market Perform	Get Alert
Apr 24, 2025	CMECME Group	$275.29	-23.35%	Kenneth WorthingtonJP Morgan 54%	211 223	Previous Underweight Current Underweight	Get Alert
Apr 23, 2025	CMECME Group	$275.29	2.8%	Benjamin BudishBarclays 74%	279 283	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 11, 2025	CMECME Group	$275.29	1.35%	Owen LauOppenheimer 64%	269 279	Previous Outperform Current Outperform	Get Alert
Apr 8, 2025	CMECME Group	$275.29	9.34%	Michael CyprysMorgan Stanley 67%	263 301	Previous Equal-Weight Current Overweight	Get Alert
Apr 8, 2025	CMECME Group	$275.29	2.8%	Patrick MoleyPiper Sandler 81%	275 283	Previous Overweight Current Overweight	Get Alert
Apr 7, 2025	CMECME Group	$275.29	1.35%	Benjamin BudishBarclays 74%	263 279	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 3, 2025	CMECME Group	$275.29	-2.28%	Ashish SabadraRBC Capital 73%	269 269	Previous Sector Perform Current Sector Perform	Get Alert
Apr 2, 2025	CMECME Group	$275.29	-20.45%	Craig SiegenthalerB of A Securities 72%	200 219	Previous Underperform Current Underperform	Get Alert
Mar 10, 2025	CMECME Group	$275.29	4.25%	Patrick O'ShaughnessyRaymond James 73%	287	Previous Market Perform Current Outperform	Get Alert
Feb 19, 2025	CMECME Gr	$275.29	-4.46%	Mike CyprysMorgan Stanley 63%	256 263	Previous Equal-Weight Current Equal-Weight	Get Alert
Feb 14, 2025	CMECME Gr	$275.29	-6.64%	Kyle VoigtKeefe, Bruyette & Woods 61%	256 257	Previous Market Perform Current Market Perform	Get Alert
Feb 13, 2025	CMECME Gr	$275.29	-2.28%	Ashish SabadraRBC Capital 73%	235 269	Previous Sector Perform Current Sector Perform	Get Alert
Feb 13, 2025	CMECME Gr	$275.29	-2.28%	Owen LauOppenheimer 64%	258 269	Previous Outperform Current Outperform	Get Alert
Feb 13, 2025	CMECME Gr	$275.29	-22.99%	Kenneth WorthingtonJP Morgan 54%	209 212	Previous Underweight Current Underweight	Get Alert
Feb 13, 2025	CMECME Gr	$275.29	-4.46%	Benjamin BudishBarclays 74%	257 263	Previous Equal-Weight Current Equal-Weight	Get Alert
Jan 13, 2025	CMECME Gr	$275.29	-7.01%	Kyle VoigtKeefe, Bruyette & Woods 61%	256 260	Previous Market Perform Current Market Perform	Get Alert
Jan 7, 2025	CMECME Gr	$275.29	-6.28%	Patrick MoleyPiper Sandler 81%	250 258	Previous Overweight Current Overweight	Get Alert
Jan 6, 2025	CMECME Gr	$275.29	-14.63%	Ashish SabadraRBC Capital 73%	235 235	Previous Sector Perform Current Sector Perform	Get Alert
Jan 6, 2025	CMECME Gr	$275.29	-9.19%	Christopher AllenCitigroup 67%	250 255	Previous Buy Current Neutral	Get Alert
Dec 20, 2024	CMECME Gr	$275.29	-5.55%	Kyle VoigtKeefe, Bruyette & Woods 61%	237 260	Previous Market Perform Current Market Perform	Get Alert
Dec 9, 2024	CMECME Gr	$275.29	-6.64%	Benjamin BudishBarclays 74%	231 257	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 11, 2024	CMECME Gr	$275.29	-17.9%	Brian BedellDeutsche Bank 73%	226 227	Previous Hold Current Hold	Get Alert
Oct 28, 2024	CMECME Gr	$275.29	-9.19%	Patrick MoleyPiper Sandler 81%	240 250	Previous Overweight Current Overweight	Get Alert
Oct 24, 2024	CMECME Gr	$275.29	-14.63%	Ashish SabadraRBC Capital 73%	235 235	Previous Sector Perform Current Sector Perform	Get Alert
Oct 24, 2024	CMECME Gr	$275.29	-6.28%	Owen LauOppenheimer 64%	245 258	Previous Outperform Current Outperform	Get Alert
Oct 24, 2024	CMECME Gr	$275.29	-7.37%	Christopher AllenCitigroup 67%	250 255	Previous Buy Current Buy	Get Alert
Oct 24, 2024	CMECME Gr	$275.29	-16.09%	Benjamin BudishBarclays 74%	219 231	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 17, 2024	CMECME Gr	$275.29	-15.36%	Mike CyprysMorgan Stanley 63%	210 233	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 14, 2024	CMECME Gr	$275.29	-11%	Owen LauOppenheimer 64%	228 245	Previous Outperform Current Outperform	Get Alert
Oct 8, 2024	CMECME Gr	$275.29	-11.37%	Simon ClinchRedburn Atlantic 59%	244	Previous Buy Current Neutral	Get Alert
Oct 8, 2024	CMECME Gr	$275.29	-12.82%	Patrick MoleyPiper Sandler 81%	225 240	Previous Overweight Current Overweight	Get Alert
Oct 7, 2024	CMECME Gr	$275.29	-20.45%	Benjamin BudishBarclays 74%	209 219	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 3, 2024	CMECME Gr	$275.29	-9.19%	Christopher AllenCitigroup 67%	240 250	Previous Buy Current Buy	Get Alert
Oct 3, 2024	CMECME Gr	$275.29	-28.08%	Alexander BlosteinGoldman Sachs 71%	195 198	Previous Sell Current Sell	Get Alert
Oct 3, 2024	CMECME Gr	$275.29	-14.63%	Ashish SabadraRBC Capital 73%	235 235	Previous Sector Perform Current Sector Perform	Get Alert
Oct 3, 2024	CMECME Gr	$275.29	-34.61%	Craig SiegenthalerB of A Securities 72%	177 180	Previous Underperform Current Underperform	Get Alert
Sep 27, 2024	CMECME Gr	$275.29	-14.63%	Ashish SabadraRBC Capital 73%	235	Previous Initiates Current Sector Perform	Get Alert
Sep 26, 2024	CMECME Gr	$275.29	-19.72%	Bill KatzTD Cowen 68%	221	Previous Initiates Current Hold	Get Alert
Sep 3, 2024	CMECME Gr	$275.29	-35.7%	Craig SiegenthalerB of A Securities 72%	177 212	Previous Neutral Current Underperform	Get Alert
Aug 20, 2024	CMECME Gr	$275.29	-18.27%	Patrick MoleyPiper Sandler 81%	225 225	Previous Overweight Current Overweight	Get Alert
Aug 15, 2024	CMECME Gr	$275.29	-27.35%	Brian BedellDeutsche Bank 73%	193 200	Previous Hold Current Hold	Get Alert
Jul 25, 2024	CMECME Gr	$275.29	-29.89%	Brian BedellDeutsche Bank 73%	193 195	Previous Hold Current Hold	Get Alert
Jul 25, 2024	CMECME Gr	$275.29	-30.62%	Kenneth WorthingtonJP Morgan 54%	187 191	Previous Underweight Current Underweight	Get Alert
Jul 25, 2024	CMECME Gr	$275.29	-22.63%	Kyle VoigtKeefe, Bruyette & Woods 61%	212 213	Previous Market Perform Current Market Perform	Get Alert

Recent Analyst Stock Rating News

PRO

BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.

PRO

Jefferies Maintains Buy on J.Jill, Raises Price Target to $25

Jefferies analyst Corey Tarlowe maintains J.Jill (NYSE:JILL) with a Buy and raises the price target from $16 to $25.

PRO

Jefferies Maintains Hold on ODDITY Tech, Raises Price Target to $18

Jefferies analyst Brian Tanquilut maintains ODDITY Tech (NASDAQ:ODD) with a Hold and raises the price target from $16 to $18.

PRO

Jefferies Initiates Coverage On Pursuit Attractions with Buy Rating, Announces Price Target of $61

Jefferies analyst Anthony Berni initiates coverage on Pursuit Attractions (NYSE:PRSU) with a Buy rating and announces Price Target of $61.

PRO

Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.

PRO

Jefferies Initiates Coverage On Lindblad Expeditions with Hold Rating, Announces Price Target of $29

Jefferies analyst Anthony Berni initiates coverage on Lindblad Expeditions (NASDAQ:LIND) with a Hold rating and announces Price Target of $29.

PRO

Jefferies Upgrades UGI to Buy, Raises Price Target to $43

Jefferies analyst Julien Dumoulin-Smith upgrades UGI (NYSE:UGI) from Hold to Buy and raises the price target from $40 to $43.

PRO

Jefferies Initiates Coverage On Liberty Media with Buy Rating, Announces Price Target of $115

Jefferies analyst Anthony Berni initiates coverage on Liberty Media (NASDAQ:FWONK) with a Buy rating and announces Price Target of $115.

PRO

Loop Capital Initiates Coverage On Dave with Buy Rating, Announces Price Target of $500

Loop Capital analyst Reginald Smith initiates coverage on Dave (NASDAQ:DAVE) with a Buy rating and announces Price Target of $500.

PRO

Loop Capital Initiates Coverage On Upstart Holdings with Hold Rating, Announces Price Target of $34

Loop Capital analyst Reginald Smith initiates coverage on Upstart Holdings (NASDAQ:UPST) with a Hold rating and announces Price Target of $34.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website